Jaypirca (Pirtobrutinib)) for Lymphoma

Overview
Jaypirca is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat some cases of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Jaypirca is indicated in cases of MCL that has returned after treatment (relapsed) or become resistant to treatment (refractory) after at least two other lines of therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. Jaypirca is indicated in cases of CLL/SLL when two lines of therapy, including a BTK inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor, have already been tried. Jaypirca is also referred to by its drug name, pirtobrutinib.

Jaypirca is used as targeted therapy for blood cancers. Jaypirca is a member of a class of drugs called kinase inhibitors. Jaypirca is believed to work by inhibiting replication and triggering cell death in cancer cells.

How do I take it?
Prescribing information states that Jaypirca is taken orally once daily.

Jaypirca comes in tablet form.

Side effects
The FDA-approved label for Jaypirca lists common side effects including fatigue, muscle and joint pain, COVID-19, bruising, and cough.

Rare but serious side effects listed for Jaypirca include infections, abnormal bleeding, abnormal heart rhythm, and other types of cancer. If taken during pregnancy, Jaypirca may cause fetal harm.

For more details about this treatment, visit:

Jaypirca — Eli Lilly and Company
https://www.jaypirca.com/